Best Practices Treatment Guideline for Depression
Based on 2010 APA Practice Guidelines and NeuroStar TMS Therapy® Indication for Use.¹

First Line Treatment Attempts

4-6 Weeks

TMS
Non-Invasive
Non-Systemic

TMS Side Effects
☐ Scalp Pain or Discomfort at Treatment Site

Single Antidepressant Medication Maintenance

Antidepressant Switch
☐ Non MAOI Class
☐ MAOIs / TCAs

Augmentation Strategies

Atypical Antipsychotic Augmentation

On-going Multiple Antidepressant Medication Maintenance

2 Months

4 Months

6 Months+

Systemic Drug Side Effects
Most common side effects per antidepressant medication labels (5% and 2x placebo)

☐ Weight Gain
☐ Nervousness
☐ Weakness
☐ Abnormal Ejaculation

☐ Constipation
☐ Anxiety
☐ Dry Mouth
☐ Impotence

☐ Diarrhea
☐ Increased Appetite
☐ Dizziness
☐ Sweating

☐ Nausea
☐ Decreased Appetite
☐ Fatigue
☐ Tremor

☐ Drowsiness
☐ Decreased Sexual Interest
☐ Headache/ Migraine
☐ Treatment Discontinuation Side Effects

☐ Insomnia

Other Treatments

☐ Edronax® (reboxetine)
☐ Remeron® (mirtazapine)
☐ Trazadone

☐ Cymbalta® (duloxetine)
☐ Effexor® (venlafaxine)
☐ Pristiq® (desvenlafaxine)

Other:

SSRI
☐ Celexa® (citalopram)
☐ Lexapro® (escitalopram)
☐ Prozac® (fluoxetine)
☐ Luvox® (fluvoxamine)
☐ Paxil® (paroxetine)
☐ Zoloft® (sertraline)
☐ other:

DNRI
☐ Wellbutrin® (bupropion)

SNRI
☐ Cymbalta® (duloxetine)
☐ Effexor® (venlafaxine)
☐ Pristiq® (desvenlafaxine)

Other:

© 2010 Neuronetics, Inc., Malvern, PA

1. Adapted from Star*D Study
As Medication Increases, So Can Side Effects and the Potential for Treatment Failure

NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

In clinical trials, patients treated with active NeuroStar TMS Therapy experienced an average reduction in their depression symptom score of 22.1% compared to a 9% reduction in patients receiving inactive treatment.

In an open-label clinical trial, most like real-world clinical practice, 1 out of 2 patients treated with NeuroStar TMS Therapy experienced significant improvement in depression symptoms. 1 out of 3 experienced complete symptom relief at the end of six weeks.

STAR*D Study demonstrates current treatment has limited effectiveness

Likelihood of achieving remission is limited and declines with each successive treatment attempt

NeuroStar TMS Therapy is available by prescription only. For full prescribing and safety information, please visit: www.NeuroStar.com


NeuroStar, Celexa, Lexapro, Prozac, Luvox, Paxil, Zoloft, Wellbutrin, Cymbalta, Effexor, Pristiq, Edronax, and Remeron are registered trademarks of their manufacturer.